We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$82.5B
AUM Growth
+$5.26B
(+6.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
962
New
129
Increased
342
Reduced
292
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$429M |
| 2 |
Airbnb
ABNB
|
+$235M |
| 3 |
T-Mobile US
TMUS
|
+$156M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$139M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deere & Co
DE
|
+$488M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$222M |
| 3 |
Expeditors International
EXPD
|
+$191M |
| 4 |
Qualcomm
QCOM
|
+$187M |
| 5 |
CERN
Cerner Corp
CERN
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.12% |
| 2 | Consumer Discretionary | 15.99% |
| 3 | Communication Services | 13.72% |
| 4 | Healthcare | 12.84% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
State Street Blackstone Senior Loan ETF
SRLN
$5.36B
| $5.81M | 0.01% |
125,441
| – | – |
|
402
Utah Medical Products
UTMD
$225M
| $5.24M | 0.01% |
61,672
+21,302
| +53% | +$1.84M |
|
403
Garrett Motion
GTX
$5.57B
| $5.2M | 0.01% |
+652,115
| New | +$4.79M |
|
|
AMWD
404
DELISTED
American Woodmark
AMWD
| $5.18M | 0.01% |
63,382
-65,040
| -51% | -$6.09M |
|
405
AZZ Inc
AZZ
$4.54B
| $4.82M | 0.01% |
93,060
+399
| +0.4% | +$21K |
|
406
Battalion Oil
BATL
$28.8M
| $4.77M | 0.01% |
356,094
-5,293
| -1% | -$66.3K |
|
|
NXDT
407
NexPoint Diversified Real Estate Trust
NXDT
$238M
| $4.68M | 0.01% |
340,284
| – | – |
|
|
RAVN
408
DELISTED
Raven Industries Inc
RAVN
| $4.18M | 0.01% |
72,334
-181,421
| -71% | -$7.89M |
|
409
Thryv Holdings
THRY
$108M
| $3.78M | ﹤0.01% |
+105,789
| New | +$2.99M |
|
410
AT&T
T
$163B
| $3.66M | ﹤0.01% |
168,425
-77
| -0% | -$1.75K |
|
|
VTA
411
DELISTED
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
| $3.6M | ﹤0.01% |
303,453
+5,813
| +2% | +$67.5K |
|
412
VSE Corp
VSEC
$6.12B
| $3.51M | ﹤0.01% |
+70,979
| New | +$3.26M |
|
413
Core Laboratories
CLB
$521M
| $3.21M | ﹤0.01% |
82,522
+1,655
| +2% | +$59.3K |
|
414
Nike
NKE
$61.9B
| $2.89M | ﹤0.01% |
18,719
+5,793
| +45% | +$780K |
|
415
GDS Holdings
GDS
$6.41B
| $2.77M | ﹤0.01% |
35,266
+1,425
| +4% | +$111K |
|
416
Booking.com
BKNG
$161B
| $2.65M | ﹤0.01% |
30,225
+2,025
| +7% | +$189K |
|
417
Invesco Senior Income Trust
VVR
$454M
| $2.58M | ﹤0.01% |
579,194
+8,449
| +1% | +$36.1K |
|
418
California Resources
CRC
$4.62B
| $2.54M | ﹤0.01% |
84,128
| – | – |
|
|
VNET
419
VNET Group
VNET
$2.09B
| $2.5M | ﹤0.01% |
108,771
-544
| -0.5% | -$13.9K |
|
420
Applied Materials
AMAT
$428B
| $2.48M | ﹤0.01% |
17,436
+4,871
| +39% | +$654K |
|
421
KLA
KLAC
$259B
| $2.42M | ﹤0.01% |
74,610
+6,900
| +10% | +$221K |
|
|
DESP
422
DELISTED
Despegar.com
DESP
| $2.41M | ﹤0.01% |
182,388
-18,760
| -9% | -$253K |
|
423
Nuveen Floating Rate Income Fund
JFR
$1.25B
| $2.37M | ﹤0.01% |
236,650
| – | – |
|
424
ExxonMobil
XOM
$634B
| $2.17M | ﹤0.01% |
34,323
+2,776
| +9% | +$166K |
|
425
Target
TGT
$68B
| $2.02M | ﹤0.01% |
8,342
-126
| -1% | -$27.6K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2021 Portfolio in Review
As of Q2 2021, Loomis, Sayles & Company held 962 positions worth $82.5B, up 6.8% from $77.2B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Loomis, Sayles & Company's Q2 2021 filing shows 129 new, 342 increased, 292 reduced and 136 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 946,065 shares worth $160M. The largest sale was Deere & Co, an estimated $488M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q2 2021 buy was Alnylam Pharmaceuticals: 946,065 shares worth $160M.
- Loomis, Sayles & Company added most to Vertex Pharmaceuticals in Q2 2021, an estimated $429M increase.
- Loomis, Sayles & Company's biggest Q2 2021 reduction was Deere & Co, cutting an estimated $488M.
- Loomis, Sayles & Company fully exited Goosehead Insurance in Q2 2021, selling an estimated $66.6M.
- Loomis, Sayles & Company's ten largest holdings make up 39% of its $82.5B portfolio in Q2 2021.
- Loomis, Sayles & Company opened 129 new positions and closed 136 in Q2 2021.
- Loomis, Sayles & Company's portfolio value rose 6.8% quarter-over-quarter to $82.5B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.